Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST)

被引：0
|
作者：
Qiu, Haibo
Zhou, Zhi-Wei
Zhou, Ye
Wan, Xiangbin
Li, Ning
Tao, Kaixiong
Li, Yong
Wu, Xin
Chen, Zi
Liu, Lihui
Men, Lichuang
Wang, Hengbang
Liang, Eric
Wang, Cunlin
Jiang, Lixin
Yang, Dajun
Xu, Rui-Hua
Zhai, Yifan
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Med Coll, Wuhan, Peoples R China
[5] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[6] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[7] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[8] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11540
引用
收藏
页数：1
相关论文
共 33 条
  • [1] Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST)
    Qiu, H.
    Zhou, Z.
    Zhou, Y.
    Wan, X.
    Li, N.
    Tao, K.
    Li, Y.
    Wu, X.
    Chen, Z.
    Liu, L.
    Men, L.
    Wang, H.
    Liang, E.
    Min, P.
    Wang, C.
    Jiang, L.
    Yang, D.
    Zhai, Y.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1053 - S1054
  • [2] Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).
    Qiu, Haibo
    Zhou, Zhiwei
    Zhou, Ye
    Wan, XiangBin
    Tao, Kaixiong
    Li, Yong
    Wu, Xin
    Liu, Lihui
    Chen, Zi
    Men, Lichuang
    Liang, Zhiyan
    Lu, Ming
    Jiang, Lixin
    Yang, Dajun
    Xu, Rui-Hua
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma.
    Qiu, Haibo
    Zhou, Zhi-wei
    Zhou, Ye
    Chen, Jie
    Wan, Xiangbin
    Li, Ning
    Tao, Kaixiong
    Li, Yong
    Wu, Xin
    Chen, Zi
    Liu, Lihui
    Yang, Chen
    Men, Lichuang
    Wang, Hengbang
    Liang, Eric
    Wang, Cunlin
    Jiang, Lixin
    Yang, Dajun
    Zhai, Yifan
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA)
    Qiu, H.
    Yang, C.
    Zhou, Z.
    Zhou, Y.
    Wan, X.
    Li, N.
    Tao, K.
    Li, Y.
    Wu, X.
    Chen, Z.
    Men, L.
    Xiong, Y.
    Liang, E.
    Wang, C.
    Yang, D.
    Zhai, Y.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1032 - S1032
  • [5] Health-Related Quality of Life (HRQOL) in Patients (Pts) with Tyrosine Kinase Inhibitor(TKI)-Resistant Chronic Myeloid Leukemia (CML) Receiving Olverembatinib (HQP1351) Therapy
    Yu, Lu
    Men, Lichuang
    Li, Zongru
    Huang, Xiaojun
    Jiang, Qian
    BLOOD, 2023, 142
  • [6] Olverembatinib, a novel multikinase inhibitor, demonstrates superior antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms
    Xiong, Yan
    Liang, Eric
    Min, Ping
    Yu, Huidan
    Wu, Bingxing
    Zhai, Guoqin
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
    Qian, Jiang
    Shi, Dayu
    Li, Zongru
    Qin, Yazhen
    Zhao, Ting
    Liu, Bingcheng
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Huan, Xiaojun
    BLOOD, 2021, 138
  • [8] Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
    Sako, Hiroyuki
    Fukuda, Kazumasa
    Saikawa, Yoshiro
    Nakamura, Rieko
    Takahashi, Tsunehiro
    Wada, Norihito
    Kawakubo, Hirohumi
    Takeuchi, Hiroya
    Ohmori, Tai
    Kitagawa, Yuko
    PLOS ONE, 2014, 9 (09):
  • [9] A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
    Jiang, Qian
    Li, Zongru
    Qin, Ya-Zhen
    Zhao, Ting
    Liu, Bingcheng
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiao-Jun
    BLOOD, 2022, 140
  • [10] Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study
    Jiang, Qian
    Li, Zongru
    Zhang, Gongli
    Hu, Yu
    Li, Weiming
    Song, Yongping
    Li, Junmin
    Zhou, Li
    Liu, Bingcheng
    Liu, Xiaoli
    Xu, Na
    Chen, Suning
    Liu, Zhenfang
    Zhu, Huanling
    Jin, Jie
    Huang, He
    Qian, Sixuan
    Meng, Li
    Du, Xin
    Zhao, Xielan
    Gao, Sujun
    Liang, Yang
    Hou, Ming
    Wang, Wei
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiaojun
    BLOOD, 2023, 142
1234